ESTRO 2024 - Abstract Book

S1402

Clinical - Head & neck

ESTRO 2024

PBM is recommended (MASCC/ISOO, ESMO) in clinical practice for OM in HNC and for radiodermitis in breast cancer but more studies are necessary to extend this therapy in others range. This study provides real world evidence that PBM has an important role in decreasing the incidence and the severity of sides effects induced by chemoradiotherapy in HNC patients while preserving an excellent oncological outcome profile.

Keywords: Photobiomodulation, toxicities, outcomes

References:

Behroozian T, Goldshtein D, Ryan Wolf J, van den Hurk C, Finkelstein S, Lam H, Patel P, Kanee L, Lee SF, Chan AW, Wong HCY, Caini S, Mahal S, Kennedy S, Chow E, Bonomo P; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review. EClinicalMedicine. 2023 Mar 27;58:101886. doi: 10.1016/j.eclinm.2023.101886. PMID: 37181415; PMCID: PMC10166790. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014 May 15;120(10):1453-61. doi: 10.1002/cncr.28592. Epub 2014 Feb 25. Erratum in: Cancer. 2015 Apr 15;121(8):1339. PMID: 24615748; PMCID: PMC4164022

2472

Proffered Paper

The effect of primary radiotherapy in oropharynx cancer: A phase IV population-based DAHANCA study

Pernille Lassen 1,2 , Jan Alsner 1 , Claus A Kristensen 3 , Christian Maare 2 , Hanne Primdahl 4 , Jørgen Johansen 5 , Maria Andersen 6 , Mohammad Farhadi 7 , Jesper G Eriksen 1 , Jens Overgaard 1 1 Aarhus University Hospital, Experimental Clinical Oncology, Aarhus, Denmark. 2 Herlev Hospital Copenhagen University, Oncology, Herlev, Denmark. 3 Rigshospitalet, Copenhagen University Hospital, Oncology, Copenhagen, Denmark. 4 Aarhus University Hospital, Oncology, Aarhus, Denmark. 5 Odense University Hospital, Oncology, Odense, Denmark. 6 Aalborg Univeristy Hospital, Oncology, Aalborg, Denmark. 7 Næstved Hospital, Oncology, Næstved, Denmark

Purpose/Objective:

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) in Denmark has increased more than fourfold for both men and women during the past 35 years, primarily driven by a rise in tumors with Human papillomavirus (HPV)-related p16-expression. This development, combined with a gradual intensification of standard treatment,